Patents by Inventor Kyeung Min Joo
Kyeung Min Joo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230213501Abstract: The present invention relates to a system for screening personalized anticancer agents, a method for screening personalized anticancer agents using the system, and an apparatus for screening personalized anticancer agents. When the inventive system for screening personalized anticancer agents is used, an anticancer agent showing an optimal anticancer activity against cancer cells collected from a patient can be selected from a variety of anticancer agents, and it is possible to previously examine a therapeutic response that can appear when the selected anticancer agent is administered into the patient. Thus, the risk of trial and error in cancer therapy can be reduced, and the cost and time required for cancer therapy can be reduced.Type: ApplicationFiled: February 24, 2023Publication date: July 6, 2023Inventors: Do Hyun NAM, Kyeung Min JOO
-
Publication number: 20220243175Abstract: The present invention relates to a method for isolating and culturing neural stem cells with high efficiency, which may shorten the time for isolation and culture by simplifying a method for isolating and culturing neural stem cells and may increase the acquisition yield of neural stem cells. The present invention provides a method for isolating and culturing neural stem cells with high efficiency, comprising the steps of adding brain tissue into an enzyme solution so as to subject the brain tissue to enzyme treatment; physically isolating cell clumps from the enzyme treated brain tissue by dividing the cell clumps according to size and removing impurities; and inoculating the cell clumps on a culture dish so as to subculture.Type: ApplicationFiled: January 30, 2019Publication date: August 4, 2022Inventors: Kyeung Min Joo, Hyun Nam
-
Publication number: 20210009950Abstract: The present invention relates to an angiogenesis-inducing method using neural stem cells. According to the present invention, neural stem cells derived from human brain tissues release MCP-1 or Gro, thus exhibiting an angiogenesis-inducing effect. When CoCl2 was treated to the neural stem cells of the present invention and when the neural stem cells were cultured in a hypoxia chamber, it was observed that a hypoxia condition increased the release amounts of MCP-1 and Gro. Therefore, the human brain tissue-derived neural stem cells of the present invention can be used to induce angiogenesis.Type: ApplicationFiled: January 30, 2019Publication date: January 14, 2021Inventors: Kyeung Min Joo, Hyun Nam
-
Publication number: 20200110071Abstract: The present invention relates to a system for screening personalized anticancer agents, a method for screening personalized anticancer agents using the system, and an apparatus for screening personalized anticancer agents. When the inventive system for screening personalized anticancer agents is used, an anticancer agent showing an optimal anticancer activity against cancer cells collected from a patient can be selected from a variety of anticancer agents, and it is possible to previously examine a therapeutic response that can appear when the selected anticancer agent is administered into the patient. Thus, the risk of trial and error in cancer therapy can be reduced, and the cost and time required for cancer therapy can be reduced.Type: ApplicationFiled: December 6, 2019Publication date: April 9, 2020Inventors: Do Hyun NAM, Kyeung Min JOO
-
Publication number: 20190374681Abstract: The present invention relates to a method for cultivation and isolation of neural stem cells whereby neural stem cells can be rapidly proliferated on mass scale and isolated at high efficiency and to a stroke patient-derived human adult neural stem cell, cultured and isolated thereby, for use in transplantation.Type: ApplicationFiled: February 23, 2018Publication date: December 12, 2019Inventors: Kyeung-Min JOO, Hyun NAM, Do-Hyun NAM, Seung-Chyul HONG, Je-Young YEON
-
Patent number: 9750826Abstract: Provided is a method for producing a glioblastoma mouse model and the mouse model produced thereby, the method including the steps of: (a) dividing a glioblastoma tissue, isolated from a patient, into 4 or more sections, and collecting one or more pieces from each of the sections; (b) dissociating a mixture of the collected pieces into glioblastoma cells as single cells; and (c) orthotopically transplanting a graft sample containing the glioblastoma cells obtained in step (b), into the brain of an immunodeficient mouse. Further provided are a method of screening a glioblastoma therapeutic agent using the mouse model and a method of providing information for selection of a patient-specific glioblastoma therapy using the mouse model. The glioblastoma mouse model shows the same genetic, morphological and pathological characteristics as those of the parental tumor, and it allows screening patient-specific glioblastoma therapeutic agent or selecting safer and more effective patient-specific glioblastoma therapy.Type: GrantFiled: June 21, 2013Date of Patent: September 5, 2017Assignee: SAMSUNG LIFE PUBLIC WELFARE FOUNDATIONInventors: Do Hyun Nam, Ju Yuon Jin, Kyeung Min Joo
-
Patent number: 9562891Abstract: A screening method is described for selecting patient-specific anti-cancer agents reflecting individual genetic properties, in a precise and rapid manner, using an extremely small amount of cancer cells. Such screening method is useful for development of novel anti-cancer agents and the personalized medical field.Type: GrantFiled: March 27, 2014Date of Patent: February 7, 2017Assignee: SAMSUNG LIFE PUBLIC WELFARE FOUNDATIONInventors: Do Hyun Nam, Kyeung Min Joo, YeonSook Choi
-
Patent number: 9493739Abstract: The present invention relates to stem cells in which a gene that activates signaling is introduced and to a method for proliferating the stem cells. More specifically, the invention relates to a method of significantly increasing the ability of stem cells to proliferate, either by transfecting stem cells with the Notch intracellular domain (NICD) to activate the Notch signaling pathway, or by transfecting stem cells with the c-MET gene and treating the transfected stem cells with the HGF ligand protein to activate the c-MET/HGF signaling pathway. According to the present invention, as a result of activating the Notch signaling pathway or the c-MET/HGF signaling pathway, stem cells having an excellent ability to proliferate can be produced in large amounts. Particularly, since neural stem cells which have been difficult to culture in vitro can be proliferated in large amounts, thus the neural stem cells will be more useful for the preparation of cell therapeutic agents for treating cranial nerve diseases.Type: GrantFiled: July 22, 2014Date of Patent: November 15, 2016Assignee: SAMSUNG LIFE PUBLIC WELFARE FOUNDATIONInventors: Do Hyun Nam, Seung Chyul Hong, Bong gu Kang, Kyeung Min Joo
-
Publication number: 20160103119Abstract: The present invention relates to a system for screening personalized anticancer agents, a method for screening personalized anticancer agents using the system, and an apparatus for screening personalized anticancer agents. When the inventive system for screening personalized anticancer agents is used, an anticancer agent showing an optimal anticancer activity against cancer cells collected from a patient can be selected from a variety of anticancer agents, and it is possible to previously examine a therapeutic response that can appear when the selected anticancer agent is administered into the patient. Thus, the risk of trial and error in cancer therapy can be reduced, and the cost and time required for cancer therapy can be reduced.Type: ApplicationFiled: December 11, 2013Publication date: April 14, 2016Inventors: Do Hyun NAM, Kyeung Min JOO
-
Patent number: 9296817Abstract: The antibody of the invention has high specificity to human c-Met and is cross-reactive to mouse c-Met. The antibody or its antigen-binding fragment of the invention is capable of specifically binding to human c-Met as well as mouse c-Met, more accurate preclinical results can be confirmed in the efficacy evaluation using mouse tumor models. The antibody of the invention inhibits the growth of cancer cells derived from various cancers by a considerable binding affinity to c-Met and the suppression of c-Met function therefrom, inhibits the phosphorylation of c-Met and downstream signaling molecules to suppress c-Met signaling, and inhibits neovascularization, thereby being very efficient in the prevention and treatment of cancers.Type: GrantFiled: February 20, 2014Date of Patent: March 29, 2016Assignee: SAMSUNG LIFE PUBLIC WELFARE FOUNDATIONInventors: Seok-Hyung Kim, Do-Hyun Nam, Hyun-Kyu Park, Kyeung Min Joo, Nam Kyung Lee
-
Publication number: 20150104391Abstract: Provided is a method for producing a glioblastoma mouse model and the mouse model produced thereby, the method including the steps of: (a) dividing a glioblastoma tissue, isolated from a patient, into 4 or more sections, and collecting one or more pieces from each of the sections; (b) dissociating a mixture of the collected pieces into glioblastoma cells as single cells; and (c) orthotopically transplanting a graft sample containing the glioblastoma cells obtained in step (b), into the brain of an immunodeficient mouse. Further provided are a method of screening a glioblastoma therapeutic agent using the mouse model and a method of providing information for selection of a patient-specific glioblastoma therapy using the mouse model. The glioblastoma mouse model shows the same genetic, morphological and pathological characteristics as those of the parental tumor, and it allows screening patient-specific glioblastoma therapeutic agent or selecting safer and more effective patient-specific glioblastoma therapy.Type: ApplicationFiled: June 21, 2013Publication date: April 16, 2015Applicant: SAMSUNG LIFE PUBLIC WELFARE FOUNDATIONInventors: Do Hyun Nam, Ju Yuon Jin, Kyeung Min Joo
-
Publication number: 20150101070Abstract: A screening method is described for selecting patient-specific anti-cancer agents reflecting individual genetic properties, in a precise and rapid manner, using an extremely small amount of cancer cells. Such screening method is useful for development of novel anti-cancer agents and the personalized medical field.Type: ApplicationFiled: March 27, 2014Publication date: April 9, 2015Applicant: SAMSUNG LIFE PUBLIC WELFARE FOUNDATIONInventors: Do Hyun Nam, Kyeung Min Joo, YeonSook Choi
-
Publication number: 20150031129Abstract: The present invention relates to stem cells in which a gene that activates signaling is introduced and to a method for proliferating the stem cells. More specifically, the invention relates to a method of significantly increasing the ability of stem cells to proliferate, either by transfecting stem cells with the Notch intracellular domain (NICD) to activate the Notch signaling pathway, or by transfecting stem cells with the c-MET gene and treating the transfected stem cells with the HGF ligand protein to activate the c-MET/HGF signaling pathway. According to the present invention, as a result of activating the Notch signaling pathway or the c-MET/HGF signaling pathway, stem cells having an excellent ability to proliferate can be produced in large amounts. Particularly, since neural stem cells which have been difficult to culture in vitro can be proliferated in large amounts, thus the neural stem cells will be more useful for the preparation of cell therapeutic agents for treating cranial nerve diseases.Type: ApplicationFiled: July 22, 2014Publication date: January 29, 2015Inventors: Do Hyun NAM, Seung Chyul HONG, Bong gu KANG, Kyeung Min JOO
-
Publication number: 20140370022Abstract: The antibody of the invention has high specificity to human c-Met and is cross-reactive to mouse c-Met. The antibody or its antigen-binding fragment of the invention is capable of specifically binding to human c-Met as well as mouse c-Met, more accurate preclinical results can be confirmed in the efficacy evaluation using mouse tumor models. The antibody of the invention inhibits the growth of cancer cells derived from various cancers by a considerable binding affinity to c-Met and the suppression of c-Met function therefrom, inhibits the phosphorylation of c-Met and downstream signaling molecules to suppress c-Met signaling, and inhibits neovascularization, thereby being very efficient in the prevention and treatment of cancers.Type: ApplicationFiled: February 20, 2014Publication date: December 18, 2014Applicant: Samsung Life Public Welfare FoundationInventors: Seok-Hyung KIM, Do-Hyun NAM, Hyun-Kyu PARK, Kyeung Min JOO, Nam Kyung LEE
-
Patent number: 8815581Abstract: The present invention relates to stem cells in which a gene that activates signaling is introduced and to a method for proliferating the stem cells. More specifically, the invention relates to a method of significantly increasing the ability of stem cells to proliferate, either by transfecting stem cells with the Notch intracellular domain (NICD) to activate the Notch signaling pathway, or by transfecting stem cells with the c-MET gene and treating the transfected stem cells with the HGF ligand protein to activate the c-MET/HGF signaling pathway. According to the present invention, as a result of activating the Notch signaling pathway or the c-MET/HGF signaling pathway, stem cells having an excellent ability to proliferate can be produced in large amounts. Particularly, since neural stem cells which have been difficult to culture in vitro can be proliferated in large amounts, thus the neural stem cells will be more useful for the preparation of cell therapeutic agents for treating cranial nerve diseases.Type: GrantFiled: February 1, 2011Date of Patent: August 26, 2014Assignee: Samsung Life Public Welfare FoundationInventors: Do Hyun Nam, Seung Chyul Hong, Bong gu Kang, Kyeung Min Joo
-
Publication number: 20120295348Abstract: The present invention relates to stem cells in which a gene that activates signaling is introduced and to a method for proliferating the stem cells. More specifically, the invention relates to a method of significantly increasing the ability of stem cells to proliferate, either by transfecting stem cells with the Notch intracellular domain (NICD) to activate the Notch signaling pathway, or by transfecting stem cells with the c-MET gene and treating the transfected stem cells with the HGF ligand protein to activate the c-MET/HGF signaling pathway. According to the present invention, as a result of activating the Notch signaling pathway or the c-MET/HGF signaling pathway, stem cells having an excellent ability to proliferate can be produced in large amounts. Particularly, since neural stem cells which have been difficult to culture in vitro can be proliferated in large amounts, thus the neural stem cells will be more useful for the preparation of cell therapeutic agents for treating cranial nerve diseases.Type: ApplicationFiled: February 1, 2011Publication date: November 22, 2012Applicant: SAMSUNG LIFE PUBLIC WELFARE FOUNDATIONInventors: Do Hyun Nam, Seung Chyul Hong, Bong gu Kang, Kyeung Min Joo